Excessive Daytime Sleepiness (EDS) is characterized by a difficulty to stay awake and alert during the major waking episodes of the day, with sleep occurring unintentionally or at inappropriate times of the wake period.
The International Classification of Sleep Disorders (ICSD-2) includes EDS as an essential feature for three diagnostic categories: narcolepsy, hypersomnia, and behaviorally induced insufficient sleep syndrome. However, it is also associated with a wide range of diseases, including psychiatric and neurological disorders, pulmonary, and cardiac conditions. According to the National Sleep Foundation (NSF), as many as 20% of people experience EDS, making it the number one complaint of those who visit sleep clinics for treatment. Daytime sleepiness is not a disorder itself but a symptom of conditions that can have serious health effects, such as obstructive sleep apnea or narcolepsy, or a side effect of certain medications or poor sleep habits.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-eds-market
The Excessive Daytime Sleepiness (EDS) market report also covers emerging drugs, current treatment practices, Excessive Daytime Sleepiness (EDS) market share of the individual therapies, current and forecasted Excessive Daytime Sleepiness (EDS) Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Excessive Daytime Sleepiness (EDS) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Excessive Daytime Sleepiness (EDS) Market Key Facts
-
In 2017, the highest cases of EDS were diagnosed in the US, in comparison to EU-5 and Japan.
-
Among the European countries, Germany had the highest diagnosed prevalent population of EDS with 590,827 cases, followed by France which had a diagnosed prevalent population of 487,146 in 2017.
-
Of all the EU-5 countries, France ranked second for diagnosed prevalent population of EDS. In 2017, there were a total of 487,146 diagnosed prevalent cases of EDS, which includes 60,454 cases from Parkinson’s disease, 208,136 cases from OSA, 5,872 cases from Narcolepsy, 2,684 cases from IH, and 210,000 cases from Bipolar Disorder.
-
The total diagnosed prevalent population of EDS in these five disorders in the 7MM was estimated to be 6,295,782 in 2017. On the other hand, Italy had the lowest diagnosed prevalent population of 256,062 in 2017.
-
In 2017, the diagnosed prevalent population of EDS in the United States was 2,960,518.
Key Benefits of Excessive Daytime Sleepiness (EDS) Market Report
-
Excessive Daytime Sleepiness (EDS) market report provides an in-depth analysis of Excessive Daytime Sleepiness (EDS) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
-
The Excessive Daytime Sleepiness (EDS) market report will help in developing business strategies by understanding the Excessive Daytime Sleepiness (EDS) Market trends & developments, key players, and future market competition that will shape and drive the Excessive Daytime Sleepiness (EDS) market in the upcoming years.
-
The Excessive Daytime Sleepiness (EDS) market report covers Excessive Daytime Sleepiness (EDS) current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Excessive Daytime Sleepiness (EDS) market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Excessive Daytime Sleepiness (EDS) Market
Excessive Daytime Sleepiness (EDS) market size is expected to grow by factors like an increase in the patient pool due to a rise in the prevalence of underlying medical conditions in the 7MM, and the expected entry of emerging therapies.
The Excessive Daytime Sleepiness (EDS) market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Excessive Daytime Sleepiness (EDS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Excessive Daytime Sleepiness (EDS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Excessive Daytime Sleepiness (EDS) Epidemiology
The Excessive Daytime Sleepiness (EDS) epidemiology section covers insights about the historical and current Excessive Daytime Sleepiness (EDS) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Excessive Daytime Sleepiness (EDS) Epidemiology Segmentation –
-
Total Diagnosed Prevalent Cases of EDS
-
Total Diagnosed Prevalent Cases of EDS in Different Disorder
Excessive Daytime Sleepiness (EDS) Drugs Uptake and Key Market Players
The Excessive Daytime Sleepiness (EDS) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Excessive Daytime Sleepiness (EDS) market or expected to get launched in the market during the study period. The analysis covers Excessive Daytime Sleepiness (EDS) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Companies across the globe are diligently working toward the development of novel therapies for EDS with a considerable amount of success over the years.
Excessive Daytime Sleepiness (EDS) Companies:
BenevolentAI Bio
Avadel Pharmaceuticals
Theranexus
Jazz Pharmaceuticals
Axsome Therapeutics
Bioprojet Pharma
Harmony Biosciences
And many others.
Excessive Daytime Sleepiness (EDS) Therapies covered in the report include:
BEN-2001
FT218
Xywav (JZP-258) for EDS in IH
AXS-12 (Reboxetine)
Wakix (Pitolisant) for EDS in OSA
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Excessive Daytime Sleepiness (EDS) Competitive Intelligence Analysis
4. Excessive Daytime Sleepiness (EDS) Market Overview at a Glance
5. Excessive Daytime Sleepiness (EDS) Disease Background and Overview
6. Excessive Daytime Sleepiness (EDS) Patient Journey
7. Excessive Daytime Sleepiness (EDS) Epidemiology and Patient Population
8. Excessive Daytime Sleepiness (EDS) Treatment Algorithm, Current Treatment, and Medical Practices
9. Excessive Daytime Sleepiness (EDS) Unmet Needs
10. Key Endpoints of Excessive Daytime Sleepiness (EDS) Treatment
11. Excessive Daytime Sleepiness (EDS) Marketed Products
12. Excessive Daytime Sleepiness (EDS) Emerging Therapies
13. Excessive Daytime Sleepiness (EDS) Seven Major Market Analysis
14. Attribute Analysis
15. Excessive Daytime Sleepiness (EDS) Market Outlook (7 major markets)
16. Excessive Daytime Sleepiness (EDS) Access and Reimbursement Overview
17. KOL Views on the Excessive Daytime Sleepiness (EDS) Market.
18. Excessive Daytime Sleepiness (EDS) Market Drivers
19. Excessive Daytime Sleepiness (EDS) Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-eds-market
Latest Reports By DelveInsight
Excessive Daytime Sleepiness Pipeline Insight
Excessive Daytime Sleepiness Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Excessive Daytime Sleepiness (EDS) Market.
Ulcerative Colitis Market
DelveInsight’ s “Ulcerative Colitis Market Insights, Epidemiology and Market Forecast – 2030” report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology and the Ulcerative Colitis market size, share, trends, and forecast for the seven major markets (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/